The efficacy of ciprofloxacin and doxycycline against experimental tularaemia

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue 4, 1998, Pages 461-465

  Russell, P ^a   Eley, S M ^a   Fulop, M J ^a   Bell, D L ^a   Titball, R W ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; FRANCISELLA TULARENSIS; LD 50; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; TULAREMIA;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DOXYCYCLINE; FRANCISELLA TULARENSIS; MICE; MICROBIAL SENSITIVITY TESTS; TULAREMIA;

EID: 0031960770     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.4.461     Document Type: Article

References (24)

1. Penn, R. L. (1994). Francisella tularensis (tularemia). In Principles and Practice of Infectious Diseases, 4th edn (Mandell, G. L., Bennett, J. E. & Dolin, R., Eds), pp. 2060-8. Churchill Livingstone, New York.
2. Overholt, E. L., Tigertt, W. D., Kadull, P. J., Ward, M. K., Charkes, N. D., Rene, R. M. et al. (1961). An analysis of forty-two cases of laboratory-acquired tularemia. American Journal of Medicine 30, 785-806.
3. Avery, F. W. & Barnett, T. B. (1967). Pulmonary tularemia - a report of five cases and consideration of pathogenesis and terminology. American Review of Respiratory Disease 95, 584-91.
4. Miller, R. P. & Bates, J. H. (1969). Pleuropulmonary tularemia - a review of 29 patients. American Review of Respiratory Disease 99, 31-41.
5. Butler, T. (1979). Plague and tularemia. Pediatric Clinics of North America, 26, 355-66.
6. Evans, M. E., Gregory, D. W., Schaffner, W. & McGee, Z. A. (1985). Tularemia: a 30-year experience with 88 cases. Medicine 64, 251-69.
7. Berson, R. C. & Harwell, A. B. (1948). Streptomycin in the treatment of tularemia. American Journal of the Medical Sciences 215, 243-9.
8. Lambert, H. P. & O'Grady, F. W. (1992). Antibiotic and Chemotherapy, 6th edn. Churchill Livingstone, Edinburgh.
9. Sawyer, W. D., Dangerfield, H. G., Hogge, A. L. & Crozier, D. (1966). Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriological Reviews 30, 542-8.
10. Mason, W. L., Eigelsbach, H. T., Little, S. F. & Bates, J. H. (1980). Treatment of tularemia, including pulmonary tularemia, with gentamicin. American Review of Respiratory Disease 121, 39-45.
11. Di Ninno, V. L., Cherwonogrodzky, J. W. & Wong, J. P. (1993). Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of Balb/c mice against Francisella tularensis. Journal of Infectious Diseases 168, 793-4.
12. Scheel, O., Reiersen, R. & Hoel, T. (1992). Treatment of tularemia with ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 11, 447-8.
13. Scheel, O., Hoel, T., Sandvik, T. & Berdal, B. P. (1993). Susceptibility pattern of Scandinavian Francisella tularensis isolates with regard to oral and parenteral antimicrobial agents. APMIS 101, 33-6.
14. Russell, P., Eley, S. M., Bell, D. B., Manchee, R. J. & Titball, R. W. (1996). Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. Journal of Antimicrobial Chemotherapy 37, 769-74.
15. Reed, L. J. & Muench, H. A. (1938). A simple method of estimating fifty per cent endpoints. American Journal of Hygiene 27, 493-7.
16. Baker, C. N., Hollis, D. G. & Thornsberry, C. (1985). Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth. Journal of Clinical Microbiology 22, 212-5.
17. Fortier, A. H., Nacy, C. A., Polsinelli, T. & Bhatnagar, N. (1995). Francisella tularensis, a model pathogen to study the interaction of facultative intracellular bacteria with phagocytic host cells. In Virulence Mechanisms of Bacterial Pathogens, 2nd edn (Roth, J. A., Bolin, C. A., Brogden, K. A., Minion, F. C. & Wannemuehler, M. J., Eds), pp. 133-43. American Society for Microbiology, Washington, DC.
18. Long, G. W., Oprandy, J. J., Narayanan, R. B., Fortier, A. H., Poster, K. R. & Nacy, C. A. (1993). Detection of Francisella tularensis in blood by polymerase chain reaction. Journal of Clinical Microbiology 31, 152-4.
19. Bevanger, L., Maeland, J. A. & Naess, A. I. (1988). Agglutinins and antibodies to Francisella tularensis outer membrane antigens in the early diagnosis of disease during an outbreak of tularemia. Journal of Clinical Microbiology 26, 433-7.
20. Downs, C. M., Buchele, L. & Edgar, E. P. (1949). Studies on pathogenesis and immunity in tularemia. I. The pathogenesis of tularemia in the white rat. Journal of Immunology 63, 117-33.
21. Fortier, A. H., Slayter, M. V., Ziemba, R., Meltzer, M. S. & Nacy, C. A. (1991). Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infection and Immunity 59, 2922-8.
22. Fortier, A. H., Leiby, D. A., Narayanan, R. B., Asafoadjei, E., Crawford, R. M., Nacy, C. A. et al. (1995). Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infection and Immunity 63, 1478-83.
23. Conlan, J. W. & North, R. J. (1992). Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infection and Immunity 60, 5164-71.
24. Enderlin, G., Morales, L., Jacobs, R. F. & Cross, J. T. (1994). Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clinical Infectious Diseases 19, 42-7.